Cost implications of HIV retesting for verification in Africa

Details

• Alternative Title:
  PLoS One
• Personal Author:
  Lasry, Arielle ; Kalou, Mireille B. ; Young, Paul R. ; Rurangirwa, Jacqueline ; Parekh, Bharat ; Behel, Stephanie
• Description:
  Introduction
  
  HIV misdiagnosis leads to severe individual and public health consequences. Retesting for verification of all HIV-positive cases prior to antiretroviral therapy initiation can reduce HIV misdiagnosis, yet this practice has not been not widely implemented.
  
  Methods
  
  We evaluated and compared the cost of retesting for verification of HIV seropositivity (retesting) to the cost of antiretroviral treatment (ART) for misdiagnosed cases in the absence of retesting (no retesting), from the perspective of the health care system. We estimated the number of misdiagnosed cases based on a review of misdiagnosis rates, and the number of positives persons needing ART initiation by 2020. We presented the total and per person costs of retesting as compared to no retesting, over a ten-year horizon, across 50 countries in Africa grouped by income level. We conducted univariate sensitivity analysis on all model input parameters, and threshold analysis to evaluate the parameter values where the total costs of retesting and the costs no retesting are equivalent. Cost data were adjusted to 2017 United States Dollars.
  
  Results and discussion
  
  The estimated number of misdiagnoses, in the absence of retesting was 156,117, 52,720 and 29,884 for lower-income countries (LICs), lower-middle income countries (LMICs), and upper middle-income countries (UMICs), respectively, totaling 240,463 for Africa. Under the retesting scenario, costs per person initially diagnosed were: $40, $21, and $42, for LICs, LMICs, and UMICs, respectively. When retesting for verification is implemented, the savings in unnecessary ART were $125, $43, and $75 per person initially diagnosed, for LICs, LMICs, and UMICs, respectively. Over the ten-year horizon, the total costs under the retesting scenario, over all country income levels, was $475 million, and was $1.192 billion under the no retesting scenario, representing total estimated savings of $717 million in HIV treatment costs averted.
  
  Conclusions
  
  Results show that to reduce HIV misdiagnosis, countries in Africa should implement the WHO’s recommendation of retesting for verification prior to ART initiation, as part of a comprehensive quality assurance program for HIV testing services.
  
  
• Subjects:
  AIDS Serodiagnosis Anti-HIV Agent Antiretroviral Therapy, Highly Active Cost-Benefit Analysis Developing Countries Diagnostic Errors Female Health Care Costs HIV Infections Humans Income Male

  More +
• Source:
  PLoS One. 14(7)
• Pubmed ID:
  31260467
• Pubmed Central ID:
  PMC6602186
• Document Type:
  Journal Article
• Place as Subject:
  Africa
• Location:
  Africa
• Volume:
  14
• Issue:
  7
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha256:758e297910b46cd114c462915b069e8d6da5915002e4a5f26ead7e8e33bbb236
• Download URL:
  https://stacks.cdc.gov/view/cdc/82527/cdc_82527_DS1.pdf
• File Type:
  [PDF - 519.06 KB ]